Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Q&A
The Continuous Improvement Mindset: RXO’s Jamie Harris
The veteran CFO is driving the trucking brokerage spinoff of XPO Logistics toward process efficiency, organic growth, and market share gains.
By
Vincent Ryan
| January 27, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
Allergan
Strategy
After 21 Years and a Spinoff, Profitability Finally Arrives
Ironwood Pharmaceuticals is in the black for the first time thanks to its complex spinoff of pre-commercial drug development programs.
By
David McCann
| September 24, 2019
Read More
Investor Relations
Big Health Care Companies Are Undervalued
McKesson and Walgreens are strong, healthy companies, despite recent downturns in their stock prices, a CEO in the investment field says.
By
David McCann
| July 1, 2019
Read More
M&A
Botox Maker Allergan Sold to AbbVie for $63B
AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
By
Lauren Muskett
| June 25, 2019
Read More
Risk & Compliance
Proposals to Separate Joint CEO-Board Chair Roles Go Nowhere
Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.
By
Joseph Kieffer
| July 12, 2018
Read More
Innovation
Biotech CFO Pitches Fundamentals, not Financials
Ironwood’s Tom Graney tries to focus investors on the firm’s pipeline rather than its revenue.
By
David Katz
| June 28, 2017
Read More
Strategy
Allergan Buys CoolSculpting Company for $2.4B
The acquisition of Zeltiq Aesthetics' system for using cooling to eliminate fat cells gives Allergan access to the growing body-contouring market.
By
Matthew Heller
| February 13, 2017
Read More
Risk & Compliance
Allergan Fined $15M Over Disclosure Failures
The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.
By
Matthew Heller
| January 18, 2017
Read More
Strategy
Allergan Bets on Tobira’s Liver Disease Drug
The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.
By
Matthew Heller
| September 20, 2016
Read More
Strategy
Pfizer Makes Cancer Play With Medivation Deal
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
By
Matthew Heller
| August 22, 2016
Read More
Strategy
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
By
Katie Kuehner-Hebert
| May 16, 2016
Read More
Corporate Finance
Finance Roundup for Executives
Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.
By
Kerry Maruna
| April 7, 2016
Read More
Tax
Did Treasury Target Pfizer-Allergan Inversion?
The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.
By
David Katz and Katie Kuehner-Hebert
| April 6, 2016
Read More
Tax
Clinton to Propose Crackdown on Inversions
The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.
By
Matthew Heller
| December 7, 2015
Read More
Tax
Pfizer Buys Allergan for $160B
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
By
Katie Kuehner-Hebert
| November 23, 2015
Read More
Risk & Compliance
Activist Investor Can’t Dodge Insider Trading Suit
A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.
By
Matthew Heller
| November 12, 2015
Read More
Next